Drug release mechanisms of cast lipid implants.

The aim of this work was to better understand which physicochemical processes are involved in the control of drug release from lipid implants prepared by melting and casting. Lipid implants gain steadily in importance as controlled parenteral drug delivery systems: In contrast to PLGA-based devices, no acidic microclimates are created, which can inactivate incorporated drugs. The melting and casting method offers various advantages over the commonly used direct compression technique. For example, powder de-mixing during manufacturing and highly challenging scale-up due to poor powder flowability are avoided. Importantly, broad spectra of drug release patterns can be easily provided by varying the type of lipid. The resulting drug release rates are generally lower than those of implants prepared by direct compression. This is probably due to the differences in the microstructure of the pore network of the systems. Drug or water diffusion plays a dominant role for the control of drug release, potentially combined with limited drug solubility effects, caused by the low amounts of water available within the implants. In the case of pure diffusion control, a mechanistic realistic mathematical theory is proposed, which allows for quantitative predictions of the effects of formulation parameters on the resulting drug release kinetics. Importantly, these theoretical predictions could be successfully confirmed by independent experiments. Thus, the obtained new insight into the underlying drug release mechanisms can significantly facilitate the optimization of this type of advanced drug delivery systems. This is particularly helpful if long release periods are targeted, requiring time-consuming experimental studies.

[1]  Paul Y. Wang Lipids as excipient in sustained release insulin implants , 1989 .

[2]  G. Winter,et al.  Continuous release of rh-interferon alpha-2a from triglyceride matrices. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[3]  D. Craig,et al.  Role of blooming in determining the storage stability of lipid-based dosage forms. , 2004, Journal of pharmaceutical sciences.

[4]  J. Siepmann,et al.  Drug release from lipid-based implants: elucidation of the underlying mass transport mechanisms. , 2006, International journal of pharmaceutics.

[5]  T. Blunk,et al.  Influence of wettability and surface activity on release behavior of hydrophilic substances from lipid matrices. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[6]  K. Yuen,et al.  Significance of lipid matrix aging on in vitro release and in vivo bioavailability. , 2005, International journal of pharmaceutics.

[7]  N. Medlicott,et al.  Melted glyceryl palmitostearate (GPS) pellets for protein delivery. , 2004, International journal of pharmaceutics.

[8]  J. Siepmann,et al.  Drug release mechanisms of compressed lipid implants. , 2011, International journal of pharmaceutics.

[9]  J. Siepmann,et al.  Mathematical modeling of drug delivery. , 2008, International journal of pharmaceutics.

[10]  J. Benoit,et al.  In vitro investigation of lipid implants as a controlled release system for interleukin-18. , 2006, International journal of pharmaceutics.

[11]  A. Klibanov Improving enzymes by using them in organic solvents , 2001, Nature.

[12]  Juergen Siepmann,et al.  Mechanisms controlling protein release from lipidic implants: effects of PEG addition. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[13]  J. Siepmann,et al.  Programmable implants--from pulsatile to controlled release. , 2006, International journal of pharmaceutics.

[14]  Jean-Maurice Vergnaud,et al.  Controlled Drug Release Of Oral Dosage Forms , 1993 .

[15]  Gerhard Winter,et al.  Lipid extrudates as novel sustained release systems for pharmaceutical proteins. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[16]  T. Malkin The polymorphism of glycerides , 1954 .

[17]  V. M. Knepp,et al.  Stability of Nonaqueous Suspension Formulations of Plasma Derived Factor IX and Recombinant Human Alpha Interferon at Elevated Temperatures , 1998, Pharmaceutical Research.

[18]  T. Blunk,et al.  Biocompatibility and erosion behavior of implants made of triglycerides and blends with cholesterol and phospholipids. , 2006, International journal of pharmaceutics.

[19]  Kiyotaka Sato Crystallization behaviour of fats and lipids — a review , 2001 .

[20]  Steven P Schwendeman,et al.  BSA degradation under acidic conditions: a model for protein instability during release from PLGA delivery systems. , 2006, Journal of pharmaceutical sciences.

[21]  P. Kleinebudde,et al.  Influence of structural variations on drug release from lipid/polyethylene glycol matrices. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[22]  Y. Ogawa,et al.  Novel sustained-release dosage forms of proteins using polyglycerol esters of fatty acids. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[23]  J. Schwartz,et al.  Melt Granulation and Heat Treatment for Wax Matrix-Controlled Drug Release , 2003, Drug development and industrial pharmacy.

[24]  Juergen Siepmann,et al.  New Insight into the Role of Polyethylene Glycol Acting as Protein Release Modifier in Lipidic Implants , 2007, Pharmaceutical Research.

[25]  J. Shah,et al.  Local Delivery of Vancomycin for the Prophylaxis of Prosthetic Device-Related Infections , 2005, Pharmaceutical Research.

[26]  G. Winter,et al.  Studies on the lipase induced degradation of lipid based drug delivery systems. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[27]  T. Blunk,et al.  Towards controlled release of BDNF--manufacturing strategies for protein-loaded lipid implants and biocompatibility evaluation in the brain. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[28]  V M Starov,et al.  Thermodynamic and kinetic aspects of fat crystallization. , 2006, Advances in colloid and interface science.

[29]  J. Siepmann,et al.  Lipid implants as drug delivery systems. , 2008, Expert opinion on drug delivery.

[30]  J. Shah,et al.  Efficacy and Pharmacokinetics of Site-Specific Cefazolin Delivery Using Biodegradable Implants in the Prevention of Post-operative Wound Infections , 1998, Pharmaceutical Research.

[31]  K. Mäder,et al.  pH and Osmotic Pressure Inside Biodegradable Microspheres During Erosion1 , 1999, Pharmaceutical Research.

[32]  T. Rades,et al.  Immunostimulatory lipid implants containing Quil-A and DC-cholesterol. , 2008, International journal of pharmaceutics.

[33]  N. Garti,et al.  Crystallization and polymorphism of fats and fatty acids , 1988 .